Plain-English translation of NCT06550804 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new approach called A-TEAM (Antiretroviral Therapy Electronic Adherence Monitoring) that uses a special device to monitor whether people are taking their HIV medications on schedule. If you miss a dose, the device sends you an alert right away, and if you keep missing doses, your care team is also notified so they can offer support. The goal is to help people take their medications consistently, keep their viral load undetectable, and stay healthy.
Many African American men with HIV struggle to take their medications every single day as prescribed, which can lead to the virus becoming active again and spreading to others. This study exists to see if real-time reminders and team support can help people stick with their treatment plan and prevent the virus from multiplying.
You likely qualify if…
You likely don't qualify if…
You would be in the study for 6 months. If you are randomly selected to receive the A-TEAM intervention, you'll use a special device to take your HIV medications, and the device will send you text or email alerts if it detects a missed dose on the same day. If you miss doses for multiple days in a row, your case manager and any social support person you've identified will also be notified so they can check in and help. You'll have your viral load tested before and after the study to measure how well the approach works. The control group will use the same monitoring device but won't receive the alerts or team support during this phase.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States